协议到期撂挑子，步长制药子公司起诉捷迈

Core Viewpoint - The company is facing a lawsuit related to a contract dispute involving approximately 652 million yuan, which may impact its inventory valuation and future profits [1] Group 1: Legal Issues - The company's subsidiary, Shanghai HePu, has filed a lawsuit against Jiemai Shanghai due to a contract dispute over the distribution agreement, with the court accepting the case [1] - The lawsuit involves around 550 million yuan worth of inventory that has not been transferred, posing a risk of inventory impairment [1] Group 2: Financial Performance - The company has experienced a decline in revenue for four consecutive years, with revenues of 160.07 billion yuan in 2020 dropping to an estimated 110.06 billion yuan in 2024 [2] - In the first three quarters of 2025, the company reported total revenue of 8.469 billion yuan, a slight decrease of 0.54% year-on-year, while net profit increased significantly by 177.54% to 868 million yuan [4] Group 3: Strategic Developments - The company plans to acquire six health food products for 7.5 million yuan to expand its presence in the health industry [5] - The acquisition involves obtaining the technical ownership of the products from six different independent entities, ensuring commercial production [6] Group 4: Market Performance - As of December 29, the company's stock price decreased by 1.16% to 16.26 yuan per share, with a total market capitalization of approximately 17.147 billion yuan [6]